Baxalta

File:Baxalta logo.jpg

Baxalta logo

Baxalta Incorporated was a biopharmaceutical company that specialized in developing, manufacturing, and commercializing therapies for orphan diseases and underserved conditions in hematology, immunology, and oncology. The company was a spin-off from Baxter International and became an independent entity on July 1, 2015.

History

Baxalta was created as a result of a corporate spin-off from Baxter International, a global healthcare company. The spin-off was aimed at focusing on the development and commercialization of biopharmaceutical products. On January 11, 2016, Shire announced that it would acquire Baxalta for $32 billion. The acquisition was completed on June 3, 2016, and Baxalta was integrated into Shire.

Products and Services

Baxalta's product portfolio included treatments for rare and chronic conditions in the following therapeutic areas:

Hematology

Baxalta developed therapies for bleeding disorders, including hemophilia. Their products included recombinant and plasma-derived therapies for the treatment of hemophilia A and B.

Immunology

The company offered treatments for primary immunodeficiency disorders and other immune system-related conditions. These included immunoglobulin therapies and other biologics.

Oncology

Baxalta's oncology division focused on developing treatments for various types of cancer, including hematologic malignancies and solid tumors. Their pipeline included both marketed products and investigational therapies.

Research and Development

Baxalta invested significantly in research and development to advance its pipeline of innovative therapies. The company collaborated with various academic institutions, research organizations, and other biopharmaceutical companies to enhance its R&D capabilities.

Corporate Structure

Baxalta was headquartered in Bannockburn, Illinois. The company operated globally, with a presence in over 100 countries. It employed approximately 16,000 people worldwide.

Acquisition by Shire

The acquisition by Shire was part of a strategic move to create a global leader in rare diseases and highly specialized conditions. The combined entity aimed to leverage Baxalta's expertise in hematology and immunology with Shire's existing portfolio and capabilities.

See Also

• Baxter International
• Shire (pharmaceutical company)
• Biopharmaceutical
• Hematology
• Immunology
• Oncology

External Links

This article is a stub related to pharmacology. You can help WikiMD by expanding it!